Biological therapies for inflammatory bowel disease (IBD) have, since their 
introduction over 15 years ago, been separated from so-called 'conventional 
therapies' in the therapeutic paradigm. Although the TNF inhibitor infliximab is 
known to improve IBD outcomes in many different ways, several questions remain 
regarding the optimal way to employ this drug in the clinic, which are the 
questions not yet explored in clinical trials, in part, due to the drug's high 
cost. With the introduction of biosimilar drugs, including the infliximab 
biosimilar CT-P13, the therapeutic landscape in IBD will change. Access to 
biological drugs will widen and patients will be treated earlier. The division 
between 'conventional' and 'biological' therapy will be replaced by new 
treatment paradigms. Gaps in knowledge about the best use of anti-TNF therapies 
in IBD may also be filled due to the enhanced competition between manufacturers 
and the expected lower costs of biosimilars.